2018 |
Chiaie, Delle L; Neuberger, P; Vochem, M; Lihs, A; Karck, U; Enders, M Archives of gynecology and obstetrics, 297 (6), S. 1389–1395, 2018, ISSN: 0932-0067. @article{DelleChiaie.2018, title = {No evidence of obstetrical adverse events after hyperimmune globulin application for primary cytomegalovirus infection in pregnancy: experience from a single centre}, author = {L Delle Chiaie and P Neuberger and M Vochem and A Lihs and U Karck and M Enders}, doi = {10.1007/s00404-018-4703-y}, issn = {0932-0067}, year = {2018}, date = {2018-01-01}, journal = {Archives of gynecology and obstetrics}, volume = {297}, number = {6}, pages = {1389--1395}, abstract = {PURPOSE: To determine the frequency of obstetrical adverse events and clinical outcome in infants following antenatal hyperimmune globulin (HIG) treatment for primary cytomegalovirus (CMV) infection in pregnancy. METHODS: Data from 50 women including three twin pregnancies were retrospectively evaluated. Primary infection was defined by seroconversion or the presence of CMV-specific IgM and low IgG avidity. All women received two or more infusions of HIG (200 U/kg). Congenital CMV (cCMV) infection was diagnosed by detection of CMV in amniotic fluid and/or neonatal urine. We compared gestational age (GA) at birth, head circumference (HC) and birth weight (BW) of infants in our study cohort with those of live-born infants delivered in our clinic between 2015 and 2016. RESULTS: Median gestational age at time of maternal CMV diagnosis was 13 weeks. One-hundred-forty-one maternal HIG doses were given. No HIG-related severe adverse reactions occurred. Preterm birth rate was 4.2% (2/47) in singleton pregnancies. None of the neonates had birth weight or head circumference textless 3rd percentile (textless 3P) for gestational age. There was no statistically significant difference regarding GA, BW and HC between our study cohort and the total population of live-born infants. The frequency of CMV-related sequelae in infants with cCMV infection was 10.5% (2/19) (one with bilateral hearing loss and one with mild motoric delay), both cases following first trimester maternal infection. CONCLUSION: Antenatal HIG treatment was well tolerated and not associated with prematurity or decreased birth weight. HIG application might have a favorable effect on the clinical course of congenital CMV infection}, keywords = {}, pubstate = {published}, tppubtype = {article} } PURPOSE: To determine the frequency of obstetrical adverse events and clinical outcome in infants following antenatal hyperimmune globulin (HIG) treatment for primary cytomegalovirus (CMV) infection in pregnancy. METHODS: Data from 50 women including three twin pregnancies were retrospectively evaluated. Primary infection was defined by seroconversion or the presence of CMV-specific IgM and low IgG avidity. All women received two or more infusions of HIG (200 U/kg). Congenital CMV (cCMV) infection was diagnosed by detection of CMV in amniotic fluid and/or neonatal urine. We compared gestational age (GA) at birth, head circumference (HC) and birth weight (BW) of infants in our study cohort with those of live-born infants delivered in our clinic between 2015 and 2016. RESULTS: Median gestational age at time of maternal CMV diagnosis was 13 weeks. One-hundred-forty-one maternal HIG doses were given. No HIG-related severe adverse reactions occurred. Preterm birth rate was 4.2% (2/47) in singleton pregnancies. None of the neonates had birth weight or head circumference textless 3rd percentile (textless 3P) for gestational age. There was no statistically significant difference regarding GA, BW and HC between our study cohort and the total population of live-born infants. The frequency of CMV-related sequelae in infants with cCMV infection was 10.5% (2/19) (one with bilateral hearing loss and one with mild motoric delay), both cases following first trimester maternal infection. CONCLUSION: Antenatal HIG treatment was well tolerated and not associated with prematurity or decreased birth weight. HIG application might have a favorable effect on the clinical course of congenital CMV infection |
Kagan, K O; Enders, M; Hoopmann, M; Hamprecht, K Behandlungsoptionen bei einer vorgeburtlichen CMV-Primärinfektion Artikel Frauenarzt, 59 (11), S. 854–858, 2018, ISSN: 0016-0237. @article{Kagan.2018b, title = {Behandlungsoptionen bei einer vorgeburtlichen CMV-Prim\"{a}rinfektion}, author = {K O Kagan and M Enders and M Hoopmann and K Hamprecht}, issn = {0016-0237}, year = {2018}, date = {2018-01-01}, journal = {Frauenarzt}, volume = {59}, number = {11}, pages = {854--858}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Modrow, S; Buxmann, H; Enders, M; Gembruch, U; Goelz, R; Hamprecht, K; Huzly, D; Kummer, P; Kagan, K O; Knuf, M; Mertens, T; Nennstiel-Ratzel, U; Roll, C; Wojcinski, M Management der kongenitalen Zytomegalievirus-Infektion bei Neugeborenen Artikel Kinder- und Jugendarzt, 49 (3), S. 107–117, 2018, ISSN: 1436-9559. @article{Modrow.2018b, title = {Management der kongenitalen Zytomegalievirus-Infektion bei Neugeborenen}, author = {S Modrow and H Buxmann and M Enders and U Gembruch and R Goelz and K Hamprecht and D Huzly and P Kummer and K O Kagan and M Knuf and T Mertens and U Nennstiel-Ratzel and C Roll and M Wojcinski}, issn = {1436-9559}, year = {2018}, date = {2018-01-01}, journal = {Kinder- und Jugendarzt}, volume = {49}, number = {3}, pages = {107--117}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Enders, M Ringelröteln in der Schwangerschaft: Frauenärzte im Netz Sonstige 2018. @misc{Enders.2018d, title = {Ringelr\"{o}teln in der Schwangerschaft: Frauen\"{a}rzte im Netz}, author = {M Enders}, url = {https://www.frauenaerzte-im-netz.de/erkrankungen/ringelroeteln-in-der-schwangerschaft/wichtige-hinweise/}, year = {2018}, date = {2018-01-01}, abstract = {Wichtige Hinweise zum Thema Ringelr\"{o}teln, wie z.B. bei Ringelr\"{o}teln im Umfeld sollte der Immunschutz der Schwangeren \"{u}berpr\"{u}ft werden. Dies ist eine Kassenleistung.}, keywords = {}, pubstate = {published}, tppubtype = {misc} } Wichtige Hinweise zum Thema Ringelröteln, wie z.B. bei Ringelröteln im Umfeld sollte der Immunschutz der Schwangeren überprüft werden. Dies ist eine Kassenleistung. |
Schalasta, G; Börner, A; Speicher, A; Enders, M Clinical chemistry and laboratory medicine, 56 (4), S. 634–641, 2018, ISSN: 1434-6621. @article{Schalasta.2018, title = {Evaluation of the Aptima HBV Quant assay vs. the COBAS TaqMan HBV test using the high pure system for the quantitation of HBV DNA in plasma and serum samples}, author = {G Schalasta and A B\"{o}rner and A Speicher and M Enders}, doi = {10.1515/cclm-2017-0701}, issn = {1434-6621}, year = {2018}, date = {2018-01-01}, journal = {Clinical chemistry and laboratory medicine}, volume = {56}, number = {4}, pages = {634--641}, abstract = {BACKGROUND: Proper management of patients with chronic hepatitis B virus (HBV) infection requires monitoring of plasma or serum HBV DNA levels using a highly sensitive nucleic acid amplification test. Because commercially available assays differ in performance, we compared herein the performance of the Hologic Aptima HBV Quant assay (Aptima) to that of the Roche Cobas TaqMan HBV test for use with the high pure system (HPS/CTM). METHODS: Assay performance was assessed using HBV reference panels as well as plasma and serum samples from chronically HBV-infected patients. Method correlation, analytical sensitivity, precision/reproducibility, linearity, bias and influence of genotype were evaluated. Data analysis was performed using linear regression, Deming correlation analysis and Bland-Altman analysis. RESULTS: Agreement between the assays for the two reference panels was good, with a difference in assay values vs. target textless0.5 log. Qualitative assay results for 159 clinical samples showed good concordance (88.1%; kappa=0.75; 95% confidence interval: 0.651-0.845). For the 106 samples quantitated by both assays, viral load results were highly correlated (R=0.92) and differed on average by 0.09 log, with 95.3% of the samples being within the 95% limit of agreement of the assays. Linearity for viral loads 1-7 log was excellent for both assays (R2textgreater0.98). The two assays had similar bias and precision across the different genotypes tested at low viral loads (25-1000 IU/mL). CONCLUSIONS: Aptima has a performance comparable with that of HPS/CTM, making it suitable for use for HBV infection monitoring. Aptima runs on a fully automated platform (the Panther system) and therefore offers a significantly improved workflow compared with HPS/CTM}, keywords = {}, pubstate = {published}, tppubtype = {article} } BACKGROUND: Proper management of patients with chronic hepatitis B virus (HBV) infection requires monitoring of plasma or serum HBV DNA levels using a highly sensitive nucleic acid amplification test. Because commercially available assays differ in performance, we compared herein the performance of the Hologic Aptima HBV Quant assay (Aptima) to that of the Roche Cobas TaqMan HBV test for use with the high pure system (HPS/CTM). METHODS: Assay performance was assessed using HBV reference panels as well as plasma and serum samples from chronically HBV-infected patients. Method correlation, analytical sensitivity, precision/reproducibility, linearity, bias and influence of genotype were evaluated. Data analysis was performed using linear regression, Deming correlation analysis and Bland-Altman analysis. RESULTS: Agreement between the assays for the two reference panels was good, with a difference in assay values vs. target textless0.5 log. Qualitative assay results for 159 clinical samples showed good concordance (88.1%; kappa=0.75; 95% confidence interval: 0.651-0.845). For the 106 samples quantitated by both assays, viral load results were highly correlated (R=0.92) and differed on average by 0.09 log, with 95.3% of the samples being within the 95% limit of agreement of the assays. Linearity for viral loads 1-7 log was excellent for both assays (R2textgreater0.98). The two assays had similar bias and precision across the different genotypes tested at low viral loads (25-1000 IU/mL). CONCLUSIONS: Aptima has a performance comparable with that of HPS/CTM, making it suitable for use for HBV infection monitoring. Aptima runs on a fully automated platform (the Panther system) and therefore offers a significantly improved workflow compared with HPS/CTM |
Spahr, C; Knauf-Witzens, T; Dahnert, L; Enders, M; Müller, M; Johne, R; Ulrich, R G Epidemiology and infection, 146 (1), S. 119–124, 2018, ISSN: 0950-2688. @article{Spahr.2018, title = {Detection of HEV-specific antibodies in four non-human primate species, including great apes, from different zoos in Germany}, author = {C Spahr and T Knauf-Witzens and L Dahnert and M Enders and M M\"{u}ller and R Johne and R G Ulrich}, doi = {10.1017/S0950268817002606}, issn = {0950-2688}, year = {2018}, date = {2018-01-01}, journal = {Epidemiology and infection}, volume = {146}, number = {1}, pages = {119--124}, abstract = {The hepatitis E virus (HEV) has been described in humans and various animal species in different regions of the world. However, the knowledge on natural HEV infection in non-human primates and the corresponding risk of zoonotic transmission is scarce. To determine whether primates in captivity are affected by HEV infection, we investigated 259 individual sera of clinically healthy non-human primates of 14 species from nine German zoos. Using a commercial double-antigen-sandwich ELISA and a commercial IgG ELISA, 10 animals (3.9%) reacted positive in at least one assay. Three ape species and one Old World monkey species were among the seropositive animals: bonobo (Pan paniscus), gorilla (Gorilla gorilla gorilla), lar gibbon (Hylobates lar) and drill (Mandrillus leucophaeus). Testing for anti-HEV-IgM antibodies by commercial ELISA and for viral RNA by reverse-transcription real-time polymerase chain reaction resulted in negative results for all animals indicating the absence of acute HEV infections. In the past, no clinical signs of hepatitis were recorded for the seropositive animals. The results suggest that non-human primates in zoos can get naturally and subclinically infected with HEV or related hepeviruses. Future studies should evaluate potential sources and transmission routes of these infections and their impact on human health}, keywords = {}, pubstate = {published}, tppubtype = {article} } The hepatitis E virus (HEV) has been described in humans and various animal species in different regions of the world. However, the knowledge on natural HEV infection in non-human primates and the corresponding risk of zoonotic transmission is scarce. To determine whether primates in captivity are affected by HEV infection, we investigated 259 individual sera of clinically healthy non-human primates of 14 species from nine German zoos. Using a commercial double-antigen-sandwich ELISA and a commercial IgG ELISA, 10 animals (3.9%) reacted positive in at least one assay. Three ape species and one Old World monkey species were among the seropositive animals: bonobo (Pan paniscus), gorilla (Gorilla gorilla gorilla), lar gibbon (Hylobates lar) and drill (Mandrillus leucophaeus). Testing for anti-HEV-IgM antibodies by commercial ELISA and for viral RNA by reverse-transcription real-time polymerase chain reaction resulted in negative results for all animals indicating the absence of acute HEV infections. In the past, no clinical signs of hepatitis were recorded for the seropositive animals. The results suggest that non-human primates in zoos can get naturally and subclinically infected with HEV or related hepeviruses. Future studies should evaluate potential sources and transmission routes of these infections and their impact on human health |
2017 |
Mueller, J; Dagenbach, S; Riecken, B; Klinger, C Unklare Leberraumforderung und Fieber nach Türkeiaufenthalt Artikel Der Internist, 58 (5), S. 503–506, 2017, ISSN: 0020-9554. @article{Mueller.2017, title = {Unklare Leberraumforderung und Fieber nach T\"{u}rkeiaufenthalt}, author = {J Mueller and S Dagenbach and B Riecken and C Klinger}, doi = {10.1007/s00108-017-0197-0}, issn = {0020-9554}, year = {2017}, date = {2017-01-01}, journal = {Der Internist}, volume = {58}, number = {5}, pages = {503--506}, abstract = {We report the case of a~76-year old female patient with a~hepatic mass after staying in eastern Turkey. There were no indices for malignancy or an infection with Echinococcus or Entamoeba histolytica. Finally we diagnosed a~Fascioliasis (liver fluke) and cured the patient successfully.}, keywords = {}, pubstate = {published}, tppubtype = {article} } We report the case of a~76-year old female patient with a~hepatic mass after staying in eastern Turkey. There were no indices for malignancy or an infection with Echinococcus or Entamoeba histolytica. Finally we diagnosed a~Fascioliasis (liver fluke) and cured the patient successfully. |
Rauch, S; Ritgen, J; Wißkirchen, M; Bauerfeind, U; Kohne, E; Weinstock, C A case of anti-Rd causing fetal anemia Artikel Transfusion, 57 (6), S. 1485–1487, 2017. @article{Rauch.2017, title = {A case of anti-Rd causing fetal anemia}, author = {S Rauch and J Ritgen and M Wi\sskirchen and U Bauerfeind and E Kohne and C Weinstock}, doi = {10.1111/trf.14078}, year = {2017}, date = {2017-01-01}, journal = {Transfusion}, volume = {57}, number = {6}, pages = {1485--1487}, abstract = {BACKGROUND Rd (SC4) is a low-frequency antigen of the Scianna blood group system. Only very few reports on anti-Rd in pregnancy exist. Mild to moderate hemolytic disease of the newborn caused by anti-Rd has been reported. This report may add further information on the clinical significance of anti-Rd for the fetus. CASE REPORT In a case of severe fetal anemia (hemoglobin concentration, 3.0 g/dL) repeated intrauterine transfusions were required. The strongly positive direct antiglobulin test (DAT) of the fetal red blood cells led to the diagnosis of hemolytic disease. The routine antibody screen was negative, extended testing revealed a maternal anti-Rd with a titer of 256. Both the newborn and her father were confirmed to carry the SC*01.04 allele. CONCLUSION Anti-Rd can cause fetal anemia. Low-frequency antigens including Rd are normally not present on screening cells. Antibodies directed against low-frequency antigens will usually not be detected by routine antibody screening in pregnancy. Thus, in cases of fetal anemia the DAT should always be included in the diagnostic workup.}, keywords = {}, pubstate = {published}, tppubtype = {article} } BACKGROUND Rd (SC4) is a low-frequency antigen of the Scianna blood group system. Only very few reports on anti-Rd in pregnancy exist. Mild to moderate hemolytic disease of the newborn caused by anti-Rd has been reported. This report may add further information on the clinical significance of anti-Rd for the fetus. CASE REPORT In a case of severe fetal anemia (hemoglobin concentration, 3.0 g/dL) repeated intrauterine transfusions were required. The strongly positive direct antiglobulin test (DAT) of the fetal red blood cells led to the diagnosis of hemolytic disease. The routine antibody screen was negative, extended testing revealed a maternal anti-Rd with a titer of 256. Both the newborn and her father were confirmed to carry the SC*01.04 allele. CONCLUSION Anti-Rd can cause fetal anemia. Low-frequency antigens including Rd are normally not present on screening cells. Antibodies directed against low-frequency antigens will usually not be detected by routine antibody screening in pregnancy. Thus, in cases of fetal anemia the DAT should always be included in the diagnostic workup. |
Regnath, T; Raecke, O; Enninger, A; Ignatius, R Helicobacter, 22 (1), 2017. @article{Regnath.2017, title = {Increasing metronidazole and rifampicin resistance of Helicobacter pylori isolates obtained from children and adolescents between 2002 and 2015 in southwest Germany}, author = {T Regnath and O Raecke and A Enninger and R Ignatius}, doi = {10.1111/hel.12327}, year = {2017}, date = {2017-01-01}, journal = {Helicobacter}, volume = {22}, number = {1}, abstract = {BACKGROUND Increasing antibiotic resistance has been reported for Helicobacter pylori, but data on the prevalence of antibiotic resistance of H.~pylori in pediatric patients and the development of resistance over time are sparse. METHODS Data for 610 H.~pylori isolates obtained between 2002 and 2015 from gastric biopsies of 582 (mainly treatment-na"ive) pediatric patients from southwest Germany were analyzed retrospectively regarding the antibiotic susceptibility determined by Etest and patients' characteristics. RESULTS Overall resistance to metronidazole, clarithromycin, and rifampicin was 28.7%, 23.2%, and 13.3%, respectively, while resistance to amoxicillin was rare (0.8%). Simultaneous resistance to metronidazole and clarithromycin was observed for 7.7% of the isolates, and 2.3% were resistant to metronidazole, clarithromycin, and rifampicin. Differences between primary vs secondary resistance existed for metronidazole (24.7% vs 38.8%}, keywords = {}, pubstate = {published}, tppubtype = {article} } BACKGROUND Increasing antibiotic resistance has been reported for Helicobacter pylori, but data on the prevalence of antibiotic resistance of H.~pylori in pediatric patients and the development of resistance over time are sparse. METHODS Data for 610 H.~pylori isolates obtained between 2002 and 2015 from gastric biopsies of 582 (mainly treatment-na"ive) pediatric patients from southwest Germany were analyzed retrospectively regarding the antibiotic susceptibility determined by Etest and patients' characteristics. RESULTS Overall resistance to metronidazole, clarithromycin, and rifampicin was 28.7%, 23.2%, and 13.3%, respectively, while resistance to amoxicillin was rare (0.8%). Simultaneous resistance to metronidazole and clarithromycin was observed for 7.7% of the isolates, and 2.3% were resistant to metronidazole, clarithromycin, and rifampicin. Differences between primary vs secondary resistance existed for metronidazole (24.7% vs 38.8% |
Rueda Guzmán, A; Slesak, G; Fleck, R; Ignatius, R; Oehme, R; Schäfer, J Chronisches Ulkus nach Südostasienreise bei 24hbox-jährigem Mann Artikel Der Internist, 58 (8), S. 859–862, 2017, ISSN: 0020-9554. @article{RuedaGuzman.2017, title = {Chronisches Ulkus nach S\"{u}dostasienreise bei 24hbox-j\"{a}hrigem Mann}, author = {A {Rueda Guzm\'{a}n} and G Slesak and R Fleck and R Ignatius and R Oehme and J Sch\"{a}fer}, doi = {10.1007/s00108-017-0215-2}, issn = {0020-9554}, year = {2017}, date = {2017-01-01}, journal = {Der Internist}, volume = {58}, number = {8}, pages = {859--862}, abstract = {Our report concerns a~24-year-old man with a~chronic exsudative skin lesion after a~journey to Southeast Asia. The diagnosis of melioidosis was made by the identification of Burkholderia pseudomallei from the ichor. The diagnosis was confirmed by polymerase change reaction. The patient was treated with meropenem i. v. for about 10~days and with trimethoprim/sulfamethoxazole for the following 12~weeks. Melioidosis is an endemic disease in Southeast Asia and North Australia which in some cases can run a~severe course and can have a~high fatality rate. The relevance of melioidosis becomes more important against the background of the increasing global movement of travelers and migration.}, keywords = {}, pubstate = {published}, tppubtype = {article} } Our report concerns a~24-year-old man with a~chronic exsudative skin lesion after a~journey to Southeast Asia. The diagnosis of melioidosis was made by the identification of Burkholderia pseudomallei from the ichor. The diagnosis was confirmed by polymerase change reaction. The patient was treated with meropenem i. v. for about 10~days and with trimethoprim/sulfamethoxazole for the following 12~weeks. Melioidosis is an endemic disease in Southeast Asia and North Australia which in some cases can run a~severe course and can have a~high fatality rate. The relevance of melioidosis becomes more important against the background of the increasing global movement of travelers and migration. |
Schwebke, I; Eggers, M; Gebel, J; Geisel, B; Glebe, D; Rapp, I; Steinmann, J; Rabenau, H F Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 60 (3), S. 353–363, 2017, ISSN: 1436-9990. @article{Schwebke.2017, title = {Pr\"{u}fung und Deklaration der Wirksamkeit von Desinfektionsmitteln gegen Viren zur Anwendung im human-medizinischen Bereich : Stellungnahme des Arbeitskreises Viruzidie beim Robert Koch-Institut}, author = {I Schwebke and M Eggers and J Gebel and B Geisel and D Glebe and I Rapp and J Steinmann and H F Rabenau}, doi = {10.1007/s00103-016-2509-2}, issn = {1436-9990}, year = {2017}, date = {2017-01-01}, journal = {Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz}, volume = {60}, number = {3}, pages = {353--363}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Schwebke, I; Eggers, M; Gebel, J; Geisel, B; Steinmann, J; Hübner, N-O; Rapp, I; Rabenau, H F Epidemiologisches Bulletin, (18/19), S. 171–172, 2017. @article{Schwebke.2017b, title = {H\"{a}ndedesinfektionsmittel: Welche Bedeutung und Konsequenzen hat der neue Wirkbereich „begrenzt viruzid PLUS“?}, author = {I Schwebke and M Eggers and J Gebel and B Geisel and J Steinmann and N-O H\"{u}bner and I Rapp and H F Rabenau}, doi = {10.17886/EpiBull-2017-026}, year = {2017}, date = {2017-01-01}, journal = {Epidemiologisches Bulletin}, number = {18/19}, pages = {171--172}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Pfaefflin, A; Schuster, K; Braun, R Short Centrifugation to Ameliorate Turn-Around-Time in Routine Coagulation Testing Artikel Clinical laboratory, 63 (11), S. 1945–1947, 2017, ISSN: 1433-6510. @article{Pfaefflin.2017, title = {Short Centrifugation to Ameliorate Turn-Around-Time in Routine Coagulation Testing}, author = {A Pfaefflin and K Schuster and R Braun}, doi = {10.7754/Clin.Lab.2017.170702}, issn = {1433-6510}, year = {2017}, date = {2017-01-01}, journal = {Clinical laboratory}, volume = {63}, number = {11}, pages = {1945--1947}, abstract = {BACKGROUND Fast and timely analysis of coagulation parameters is mandatory in hospital laboratories as the results are decisive for diagnosis and treatment in emergency patients. An important factor in TAT (turn-around time) prolongation is centrifugation of all samples prior to analysis. According to literature and most current SOPs (standard operation protocols) centrifugation time is given with 10 minutes at approximately 2,000 g and cannot be reduced without infringement of standards. Thus, we have attempted to minimize TAT by comparing coagulation test results achieved with 5 minutes centrifugation time vs. 10 minutes. If feasible, a shorter centrifugation time will result in further optimized TAT and therefore save critical time to treatment in emergency patients. METHODS 96 routine clinical samples were tested for prothrombin time (textquotedblQuicktextquotedbl), activated partial prothrombin time (aPTT), thrombin time, fibrinogen, antithrombin III, and D-Dimer with 5 and 10 minutes centrifugation. 405 double measurements were performed. RESULTS Correlation of results were for all 6 parameters 0.99. Deviation of the mean was lower than 3% for each parameter. 98.5% of results deviated less than 10%. Although the analysis results for prothrombin time and for antithrombin III show a formal significant difference via Student's t-test, clinically, a difference is not evident. CONCLUSIONS Shortening of centrifugation time for coagulation testing seems to have no detrimental effects on the analysis results, and might be sought for routine coagulation testing to achieve shorter turn-around time.}, keywords = {}, pubstate = {published}, tppubtype = {article} } BACKGROUND Fast and timely analysis of coagulation parameters is mandatory in hospital laboratories as the results are decisive for diagnosis and treatment in emergency patients. An important factor in TAT (turn-around time) prolongation is centrifugation of all samples prior to analysis. According to literature and most current SOPs (standard operation protocols) centrifugation time is given with 10 minutes at approximately 2,000 g and cannot be reduced without infringement of standards. Thus, we have attempted to minimize TAT by comparing coagulation test results achieved with 5 minutes centrifugation time vs. 10 minutes. If feasible, a shorter centrifugation time will result in further optimized TAT and therefore save critical time to treatment in emergency patients. METHODS 96 routine clinical samples were tested for prothrombin time (textquotedblQuicktextquotedbl), activated partial prothrombin time (aPTT), thrombin time, fibrinogen, antithrombin III, and D-Dimer with 5 and 10 minutes centrifugation. 405 double measurements were performed. RESULTS Correlation of results were for all 6 parameters 0.99. Deviation of the mean was lower than 3% for each parameter. 98.5% of results deviated less than 10%. Although the analysis results for prothrombin time and for antithrombin III show a formal significant difference via Student's t-test, clinically, a difference is not evident. CONCLUSIONS Shortening of centrifugation time for coagulation testing seems to have no detrimental effects on the analysis results, and might be sought for routine coagulation testing to achieve shorter turn-around time. |
Wellinghausen, N; Abele-Horn, M; Mantke, O D; Enders, M; Fingerle, V; Gärtner, B; Hagedorn, H J; Rabenau, Holger F; Reiter-Owona, I; Tintelnot, K; Weig, M; Zeichhardt, H; Hunfeld, K P MiQ - Immunological Methods for the Detection of Infectious Diseases Buch Dustri-Verlag Dr. Karl Feistle, Oberhaching, 2017, ISBN: 978-3-87185-518-4. @book{Wellinghausen.2017, title = {MiQ - Immunological Methods for the Detection of Infectious Diseases}, author = {N Wellinghausen and M Abele-Horn and O D Mantke and M Enders and V Fingerle and B G\"{a}rtner and H J Hagedorn and Holger F Rabenau and I Reiter-Owona and K Tintelnot and M Weig and H Zeichhardt and K P Hunfeld}, isbn = {978-3-87185-518-4}, year = {2017}, date = {2017-01-01}, volume = {1}, publisher = {Dustri-Verlag Dr. Karl Feistle}, address = {Oberhaching}, institution = {INSTAND e.V.}, keywords = {}, pubstate = {published}, tppubtype = {book} } |
Wellinghausen, N; Abele-Horn, M; Mantke, O D; Enders, M; Fingerle, V; Gärtner, B; Hagedorn, H J; Rabenau, Holger F; Reiter-Owona, I; Tintelnot, K; Weig, M; Zeichhardt, H; Hunfeld, K P MIQ 35b Infektionsimmunologische Methoden Teil II Buchkapitel mit eigenem Titel Podbielski, A; Abele-Horn, M; Becker, K; Herrmann, M; Kniehl, E; Mauch, H; Rüssmann, H (Hrsg.): MiQ: Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik, Elsevier, München, 2017, ISBN: 978-3-437-41532-6. @incollection{Wellinghausen.2017b, title = {MIQ 35b Infektionsimmunologische Methoden Teil II}, author = {N Wellinghausen and M Abele-Horn and O D Mantke and M Enders and V Fingerle and B G\"{a}rtner and H J Hagedorn and Holger F Rabenau and I Reiter-Owona and K Tintelnot and M Weig and H Zeichhardt and K P Hunfeld}, editor = {A Podbielski and M Abele-Horn and K Becker and M Herrmann and E Kniehl and H Mauch and H R\"{u}ssmann}, isbn = {978-3-437-41532-6}, year = {2017}, date = {2017-01-01}, booktitle = {MiQ: Qualit\"{a}tsstandards in der mikrobiologisch-infektiologischen Diagnostik}, publisher = {Elsevier}, address = {M\"{u}nchen}, keywords = {}, pubstate = {published}, tppubtype = {incollection} } |
Wellinghausen, N; Abele-Horn, M; Mantke, O D; Enders, M; Fingerle, V; Gärtner, B; Hagedorn, H J; Rabenau, Holger F; Reiter-Owona, I; Tintelnot, K; Weig, M; Zeichhardt, H; Hunfeld, K P MIQ 35c Infektionsimmunologische Methoden Teil III Buchkapitel mit eigenem Titel Podbielski, A; Abele-Horn, M; Becker, K; Herrmann, M; Kniehl, E; Mauch, H; Rüssmann, H (Hrsg.): MiQ: Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik, Elsevier, München, 2017, ISBN: 978-3-437-41532-6. @incollection{Wellinghausen.2017c, title = {MIQ 35c Infektionsimmunologische Methoden Teil III}, author = {N Wellinghausen and M Abele-Horn and O D Mantke and M Enders and V Fingerle and B G\"{a}rtner and H J Hagedorn and Holger F Rabenau and I Reiter-Owona and K Tintelnot and M Weig and H Zeichhardt and K P Hunfeld}, editor = {A Podbielski and M Abele-Horn and K Becker and M Herrmann and E Kniehl and H Mauch and H R\"{u}ssmann}, isbn = {978-3-437-41532-6}, year = {2017}, date = {2017-01-01}, booktitle = {MiQ: Qualit\"{a}tsstandards in der mikrobiologisch-infektiologischen Diagnostik}, publisher = {Elsevier}, address = {M\"{u}nchen}, keywords = {}, pubstate = {published}, tppubtype = {incollection} } |
Wellinghausen, N; Abele-Horn, M; Mantke, O D; Enders, M; Fingerle, V; Gärtner, B; Hagedorn, H J; Rabenau, Holger F; Reiter-Owona, I; Tintelnot, K; Weig, M; Zeichhardt, H; Hunfeld, K P MIQ 35a Infektionsimmunologische Methoden Teil I Buchkapitel mit eigenem Titel Podbielski, A; Abele-Horn, M; Becker, K; Herrmann, M; Kniehl, E; Mauch, H; Rüssmann, H (Hrsg.): MiQ: Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik, Elsevier, München, 2017, ISBN: 978-3-437-41532-6. @incollection{Wellinghausen.2017d, title = {MIQ 35a Infektionsimmunologische Methoden Teil I}, author = {N Wellinghausen and M Abele-Horn and O D Mantke and M Enders and V Fingerle and B G\"{a}rtner and H J Hagedorn and Holger F Rabenau and I Reiter-Owona and K Tintelnot and M Weig and H Zeichhardt and K P Hunfeld}, editor = {A Podbielski and M Abele-Horn and K Becker and M Herrmann and E Kniehl and H Mauch and H R\"{u}ssmann}, isbn = {978-3-437-41532-6}, year = {2017}, date = {2017-01-01}, booktitle = {MiQ: Qualit\"{a}tsstandards in der mikrobiologisch-infektiologischen Diagnostik}, publisher = {Elsevier}, address = {M\"{u}nchen}, keywords = {}, pubstate = {published}, tppubtype = {incollection} } |
Groß, U; Enders, M; Garweg, J G; Reiter-Owona, I; Schrod, L Toxoplasmose in der Schwangerschaft und beim Neugeborenen Artikel pädiatrische praxis, 87 (2), S. 187–198, 2017. @article{Gro.2017, title = {Toxoplasmose in der Schwangerschaft und beim Neugeborenen}, author = {U Gro\ss and M Enders and J G Garweg and I Reiter-Owona and L Schrod}, year = {2017}, date = {2017-01-01}, journal = {p\"{a}diatrische praxis}, volume = {87}, number = {2}, pages = {187--198}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Wagner, P; Kagan, K O; Enders, M Toxoplasmose in der Schwangerschaft Buchkapitel mit eigenem Titel Berg, C (Hrsg.): Fetale Therapie, 1 , S. 164–167, Walter de Gruyter, Berlin/Boston, 2017, ISBN: 978-3-11-043841-3. @incollection{Wagner.2017, title = {Toxoplasmose in der Schwangerschaft}, author = {P Wagner and K O Kagan and M Enders}, editor = {C Berg}, isbn = {978-3-11-043841-3}, year = {2017}, date = {2017-01-01}, booktitle = {Fetale Therapie}, volume = {1}, pages = {164--167}, publisher = {Walter de Gruyter}, address = {Berlin/Boston}, keywords = {}, pubstate = {published}, tppubtype = {incollection} } |
Enders, M; Daiminger, A; Exler, S; Enders, G Prenatal diagnosis, 37 (9), S. 940–942, 2017, ISSN: 0197-3851. @article{Enders.2017, title = {Amniocentesis for prenatal diagnosis of cytomegalovirus infection: challenging the 21 weeks' threshold}, author = {M Enders and A Daiminger and S Exler and G Enders}, doi = {10.1002/pd.5107}, issn = {0197-3851}, year = {2017}, date = {2017-01-01}, journal = {Prenatal diagnosis}, volume = {37}, number = {9}, pages = {940--942}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Enders, M; Daiminger, A; Exler, S; Ertan, K; Enders, G; Bald, R Prenatal diagnosis, 37 , S. 1–10, 2017, ISSN: 0197-3851. @article{Enders.2017b, title = {Prenatal diagnosis of congenital cytomegalovirus infection in 115 cases: a 5 years' single center experience}, author = {M Enders and A Daiminger and S Exler and K Ertan and G Enders and R Bald}, doi = {10.1002/pd.5025}, issn = {0197-3851}, year = {2017}, date = {2017-01-01}, journal = {Prenatal diagnosis}, volume = {37}, pages = {1--10}, abstract = {OBJECTIVE: The objective of this study is to investigate the diagnostic value of invasive prenatal diagnosis (PD) of congenital cytomegalovirus (CMV) infection from amniotic fluid (AF) and fetal blood (FB). METHODS: A retrospective study was conducted on 115 pregnancies with CMV primary infection. A total of 111 AF and 106 FB samples were investigated for various virological and non-virological markers. Detailed ultrasound examinations were performed at time of PD. RESULTS: Overall sensitivity of CMV PCR in FB (75.6%; 95%CI 60-87) and AF (72.7%; 95%CI 57-85) was comparable. In women with amniocentesis textgreater8 weeks between seroconversion and PD, we did not observe significant differences between amniocentesis performed textgreater/=17 + 0 (sensitivity 90.9%; 95%CI 71-99) and textgreater/=20 + 0 gestational weeks (sensitivity 90.0%; 95%CI 68-99). Virological markers in FB were higher in symptomatic compared with asymptomatic fetuses (p textless 0.05). No significant differences were observed for non-virological markers. However, platelet counts textless120 x 10e9/L and beta-2 microglobulin values textgreater14 mg/L were more frequently found in fetuses with severe ultrasound abnormalities compared with fetuses with no or mild abnormalities (p textless 0.001). CONCLUSION: Optimal timing of amniocentesis in women with primary infection in early gestation should be reevaluated in a prospective study. Analysis of FB markers may be beneficial in the individual management of pregnant women with confirmed congenital CMV infection. (c) 2017 John Wiley & Sons, Ltd}, keywords = {}, pubstate = {published}, tppubtype = {article} } OBJECTIVE: The objective of this study is to investigate the diagnostic value of invasive prenatal diagnosis (PD) of congenital cytomegalovirus (CMV) infection from amniotic fluid (AF) and fetal blood (FB). METHODS: A retrospective study was conducted on 115 pregnancies with CMV primary infection. A total of 111 AF and 106 FB samples were investigated for various virological and non-virological markers. Detailed ultrasound examinations were performed at time of PD. RESULTS: Overall sensitivity of CMV PCR in FB (75.6%; 95%CI 60-87) and AF (72.7%; 95%CI 57-85) was comparable. In women with amniocentesis textgreater8 weeks between seroconversion and PD, we did not observe significant differences between amniocentesis performed textgreater/=17 + 0 (sensitivity 90.9%; 95%CI 71-99) and textgreater/=20 + 0 gestational weeks (sensitivity 90.0%; 95%CI 68-99). Virological markers in FB were higher in symptomatic compared with asymptomatic fetuses (p textless 0.05). No significant differences were observed for non-virological markers. However, platelet counts textless120 x 10e9/L and beta-2 microglobulin values textgreater14 mg/L were more frequently found in fetuses with severe ultrasound abnormalities compared with fetuses with no or mild abnormalities (p textless 0.001). CONCLUSION: Optimal timing of amniocentesis in women with primary infection in early gestation should be reevaluated in a prospective study. Analysis of FB markers may be beneficial in the individual management of pregnant women with confirmed congenital CMV infection. (c) 2017 John Wiley & Sons, Ltd |
Chiaie, Delle L; Lihs, A; Neuberger, P; Enders, M Geburtshilfliches und neonatales Outcome nach CMV-Hyperimmunglobulin (HIG) Applikation bei primären CMV Infektion in der Schwangerschaft: Erfahrung eines Perinatalzentrums: Poster Buchkapitel mit eigenem Titel für Medizin, Deutsche Gesellschaft Perinatale (Hrsg.): 28. Deutscher Kongress für Perinatale Medizin, 221 S 01 , S. E1 - 113, 2017. @incollection{DelleChiaie.2017, title = {Geburtshilfliches und neonatales Outcome nach CMV-Hyperimmunglobulin (HIG) Applikation bei prim\"{a}ren CMV Infektion in der Schwangerschaft: Erfahrung eines Perinatalzentrums: Poster}, author = {L Delle Chiaie and A Lihs and P Neuberger and M Enders}, editor = {Deutsche Gesellschaft f\"{u}r Perinatale Medizin}, doi = {10.1055/s-0037-1607799}, year = {2017}, date = {2017-01-01}, booktitle = {28. Deutscher Kongress f\"{u}r Perinatale Medizin}, volume = {221 S 01}, pages = {E1 - 113}, series = {Zeitschrift f\"{u}r Geburtshilfe und Neonatologie}, keywords = {}, pubstate = {published}, tppubtype = {incollection} } |
2016 |
Ignatius, R; Klemm, T; Zander, S; Gahutu, J B; Kimmig, P; Mockenhaupt, F P; Regnath, T Parasitology research, 115 (3), S. 1229–1234, 2016. @article{Ignatius.2016, title = {Highly specific detection of Cryptosporidium spp. oocysts in human stool samples by undemanding and inexpensive phase contrast microscopy}, author = {R Ignatius and T Klemm and S Zander and J B Gahutu and P Kimmig and F P Mockenhaupt and T Regnath}, doi = {10.1007/s00436-015-4859-3}, year = {2016}, date = {2016-01-01}, journal = {Parasitology research}, volume = {115}, number = {3}, pages = {1229--1234}, abstract = {To compare phase contrast microscopy (PCM) of unstained slides for the detection of Cryptosporidium spp. oocysts with a commercially available enzyme immunoassay (EIA) for the detection of cryptosporidial antigen in human stool samples, we prospectively analysed by both methods 463 fresh human stool samples obtained from diarrhoeic patients between July and October 2014. Compared with the EIA, the sensitivity, specificity, positive and negative predictive value of PCM were 88.9 % (95 % confidence interval (CI), 66.0-98.1 %), 100 % (95 % CI, 99.0-100 %), 100 % (95 % CI, 77.3-100 %) and 99.6 % (95 % CI, 98.3-100 %), respectively. Additionally, we retrospectively examined with PCM 65 fixed stool samples that had been collected in 2010 from mostly asymptomatic Rwandan children textless5 years of age; 14 of these samples had previously yielded positive results with a highly sensitive real-time (RT)-PCR. PCM detected cryptosporidia in 5/14 RT-PCR-positive samples, and notably, also in one of 51 RT-PCR-negative samples, which was subsequently confirmed by acid-fast staining. Positive and negative percent agreement of PCM with RT-PCR were 35.7 % (95 % CI, 16.2-61.4 %) and 98.0 % (95 % CI, 88.7-100 %), respectively. Positive PCM results were associated with higher RT-PCR cycle threshold values (p = 0.044). In conclusion, PCM offers a highly specific, undemanding and inexpensive method for the laboratory diagnosis of acute human cryptosporidiosis independent of the causative Cryptosporidium species.}, keywords = {}, pubstate = {published}, tppubtype = {article} } To compare phase contrast microscopy (PCM) of unstained slides for the detection of Cryptosporidium spp. oocysts with a commercially available enzyme immunoassay (EIA) for the detection of cryptosporidial antigen in human stool samples, we prospectively analysed by both methods 463 fresh human stool samples obtained from diarrhoeic patients between July and October 2014. Compared with the EIA, the sensitivity, specificity, positive and negative predictive value of PCM were 88.9 % (95 % confidence interval (CI), 66.0-98.1 %), 100 % (95 % CI, 99.0-100 %), 100 % (95 % CI, 77.3-100 %) and 99.6 % (95 % CI, 98.3-100 %), respectively. Additionally, we retrospectively examined with PCM 65 fixed stool samples that had been collected in 2010 from mostly asymptomatic Rwandan children textless5 years of age; 14 of these samples had previously yielded positive results with a highly sensitive real-time (RT)-PCR. PCM detected cryptosporidia in 5/14 RT-PCR-positive samples, and notably, also in one of 51 RT-PCR-negative samples, which was subsequently confirmed by acid-fast staining. Positive and negative percent agreement of PCM with RT-PCR were 35.7 % (95 % CI, 16.2-61.4 %) and 98.0 % (95 % CI, 88.7-100 %), respectively. Positive PCM results were associated with higher RT-PCR cycle threshold values (p = 0.044). In conclusion, PCM offers a highly specific, undemanding and inexpensive method for the laboratory diagnosis of acute human cryptosporidiosis independent of the causative Cryptosporidium species. |
Eggers, M Neuer Wirksamkeitsbereich begrenzt viruzid PLUS -- was ist das? Artikel Hygiene + Medizin, 41 (12), S. 319, 2016, ISSN: 0172-3790. @article{Eggers.2016b, title = {Neuer Wirksamkeitsbereich begrenzt viruzid PLUS -- was ist das?}, author = {M Eggers}, url = {http://www.zbmed.de/ccmedimages/2016/ZBMED-2017135155-3.pdf}, issn = {0172-3790}, year = {2016}, date = {2016-01-01}, journal = {Hygiene + Medizin}, volume = {41}, number = {12}, pages = {319}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Enders, G; Enders, M; Steller, J Infektionen in der Schwangerschaft Buchkapitel mit eigenem Titel K, Goerke; J, Steller; A, Valet (Hrsg.): Klinikleitfaden Gynäkologie und Geburtshilfe, S. 201–245, Urban & Fischer, München, 2016. @incollection{Enders.2016, title = {Infektionen in der Schwangerschaft}, author = {G Enders and M Enders and J Steller}, editor = {Goerke K and Steller J and Valet A}, year = {2016}, date = {2016-01-01}, booktitle = {Klinikleitfaden Gyn\"{a}kologie und Geburtshilfe}, pages = {201--245}, publisher = {Urban & Fischer}, address = {M\"{u}nchen}, keywords = {}, pubstate = {published}, tppubtype = {incollection} } |
